N-(Phosphonacetyl)-L-Aspartate (BioDeep_00000900561)
代谢物信息卡片
N-(Phosphonacetyl)-L-Aspartate
化学式: C6H7NO8P-3 (251.9909292)
中文名称:
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: C(C(C(=O)[O-])NC(=O)CP(=O)(O)[O-])C(=O)[O-]
InChI: InChI=1S/C6H10NO8P/c8-4(2-16(13,14)15)7-3(6(11)12)1-5(9)10/h3H,1-2H2,(H,7,8)(H,9,10)(H,11,12)(H2,13,14,15)/p-3/t3-/m0/s1
描述信息
D018377 - Neurotransmitter Agents > D018846 - Excitatory Amino Acids
D000890 - Anti-Infective Agents > D000998 - Antiviral Agents
D009676 - Noxae > D000963 - Antimetabolites
D000970 - Antineoplastic Agents
D004791 - Enzyme Inhibitors
同义名列表
1 个代谢物同义名
相关代谢途径
Reactome(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
0 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
文献列表
- Robin Mathew, Sameera Kongara, Brian Beaudoin, Cristina M Karp, Kevin Bray, Kurt Degenhardt, Guanghua Chen, Shengkan Jin, Eileen White. Autophagy suppresses tumor progression by limiting chromosomal instability.
Genes & development.
2007 Jun; 21(11):1367-81. doi:
10.1101/gad.1545107. [PMID: 17510285] - Rolando A G Garcia, Liansheng Liu, Zhongyi Hu, Alexis Gonzalez, Reid W von Borstel, Joel A Saydoff. Severe cytochrome c oxidase inhibition in vivo does not induce a pyrimidine deficiency; neuroprotective action of oral uridine prodrug PN401 requires supraphysiological levels of uridine.
Brain research.
2005 Dec; 1066(1-2):164-71. doi:
10.1016/j.brainres.2005.10.056. [PMID: 16330000] - Germana Dini, Silvia Funghini, Ewa Witort, Lucia Magnelli, Elena Fanti, Daniel B Rifkin, Mario Del Rosso. Overexpression of the 18 kDa and 22/24 kDa FGF-2 isoforms results in differential drug resistance and amplification potential.
Journal of cellular physiology.
2002 Oct; 193(1):64-72. doi:
10.1002/jcp.10152. [PMID: 12209881] - J L Grem, L K Yee, B Schuler, J M Hamilton, A P Chen, C Chabuk, F Grollman, M Grabenc, C J Allegra, C H Takimoto. N-(phosphonacetyl)-L-aspartate and calcium leucovorin modulation of fluorouracil administered by constant rate and circadian pattern of infusion over 72 hours in metastatic gastrointestinal adenocarcinoma.
Annals of oncology : official journal of the European Society for Medical Oncology.
2001 Nov; 12(11):1581-7. doi:
10.1023/a:1013185125186. [PMID: 11822758] - K Amin, K Y Ng, C S Brown, M S Bruno, T D Heath. LDL induced association of anionic liposomes with cells and delivery of contents as shown by the increase in potency of liposome dependent drugs.
Pharmaceutical research.
2001 Jul; 18(7):914-21. doi:
10.1023/a:1010971808006. [PMID: 11496949] - J S Kim, T D Heath. In vitro cytotoxic effect of N-(phosphonacetyl)-L-aspartic acid in liposome against C-26 murine colon carcinoma.
Archives of pharmacal research.
2000 Apr; 23(2):167-71. doi:
10.1007/bf02975508. [PMID: 10836745] - R J Harte, J C Matthews, S M O'Reilly, D W Tilsley, S Osman, G Brown, S J Luthra, F Brady, T Jones, P M Price. Tumor, normal tissue, and plasma pharmacokinetic studies of fluorouracil biomodulation with N-phosphonacetyl-L-aspartate, folinic acid, and interferon alfa.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
1999 May; 17(5):1580-8. doi:
10.1200/jco.1999.17.5.1580. [PMID: 10334547] - X R Jiang, G Jimenez, E Chang, M Frolkis, B Kusler, M Sage, M Beeche, A G Bodnar, G M Wahl, T D Tlsty, C P Chiu. Telomerase expression in human somatic cells does not induce changes associated with a transformed phenotype.
Nature genetics.
1999 Jan; 21(1):111-4. doi:
10.1038/5056. [PMID: 9916802] - C Y Chen, J Liou, L W Forman, D V Faller. Correlation of genetic instability and apoptosis in the presence of oncogenic Ki-Ras.
Cell death and differentiation.
1998 Nov; 5(11):984-95. doi:
10.1038/sj.cdd.4400448. [PMID: 9846185] - C J Langer, D Schaebler, E Sauter, D DeMaria, C Johnson, D M Reilly, J Clark, J Leighton, C Aks, S Litwin, J A Ridge. Phase II study of N-phosphonacetyl-L-aspartate, recombinant interferon-alpha, and fluorouracil infusion in advanced squamous cell carcinoma of the head and neck.
Head & neck.
1998 Aug; 20(5):385-91. doi:
10.1002/(sici)1097-0347(199808)20:5<385::aid-hed5>3.0.co;2-u. [PMID: 9663665] - M A Nassim, M R Rouini, M C Cripps, F H Shirazi, S Veerasinghan, J M Molepo, M Obrocea, D Redmond, S Bates, D Fry, D J Stewart, R Goel. Effects of PALA on the pharmacokinetics of 5-fluorouracil.
Oncology reports.
1998 Jan; 5(1):217-21. doi:
10.3892/or.5.1.217. [PMID: 9458325] - C H Köhne, A Harstrick, W Hiddemann, P Schöffski, H Wilke, C Bokemeyer, B Dörken, H J Schmoll. Modulation of 5-fluorouracil with methotrexate and low-dose N-(phosphonacetyl)-L-aspartate in patients with advanced colorectal cancer. Results of a phase II study.
European journal of cancer (Oxford, England : 1990).
1997 Oct; 33(11):1896-9. doi:
10.1016/s0959-8049(97)00256-6. [PMID: 9470854] - B Goz, K F Bastow. A possible role for topoisomerase II in cell death and N-phosphonoacetyl-L-aspartate-resistance frequency and its enhancement by 1-beta-D-arabinofuranosyl cytosine and 5-fluoro-2'-deoxyuridine.
Mutation research.
1997 Aug; 384(2):89-106. doi:
10.1016/s0921-8777(97)00016-5. [PMID: 9298118] - A R Kinsella, D Smith, M Pickard. Resistance to chemotherapeutic antimetabolites: a function of salvage pathway involvement and cellular response to DNA damage.
British journal of cancer.
1997; 75(7):935-45. doi:
10.1038/bjc.1997.164. [PMID: 9083327] - M Pickard, A Kinsella. Influence of both salvage and DNA damage response pathways on resistance to chemotherapeutic antimetabolites.
Biochemical pharmacology.
1996 Aug; 52(3):425-31. doi:
10.1016/0006-2952(96)00244-4. [PMID: 8687496] - A Hageboutros, G R Hudes, J Brennan, F Green, J Hoffman, F P LaCreta, J Colofiore, D S Martin, R F Ozols, P J O'Dwyer. Phase I trial of fluorouracil modulation by N-phosphonacetyl-L-aspartate and 6-methylmercaptopurine ribonucleoside.
Cancer chemotherapy and pharmacology.
1996; 37(3):229-34. doi:
10.1007/bf00688321. [PMID: 8529282] - P R Wyde, D K Moore, D M Pimentel, H A Blough. Evaluation of the antiviral activity of N-(phosphonoacetyl)-L-aspartate against paramyxoviruses in tissue culture and against respiratory syncytial virus in cotton rats.
Antiviral research.
1995 May; 27(1-2):59-69. doi:
10.1016/0166-3542(94)00080-r. [PMID: 7486959] - L Tessera, E Mucciolo, L Bertoni, E Giulotto. Selection of N-(phosphonacetyl)-L-aspartate resistant Chinese hamster mutants in the presence of the uridine uptake inhibitor dipyridamole.
Anticancer research.
1995 Jan; 15(1):189-92. doi:
NULL. [PMID: 7733632] - B Ramachandran, K Houben, Y Y Rozenberg, J R Haigh, A Varpetian, B D Howard. Differential expression of transporters for norepinephrine and glutamate in wild type, variant, and WNT1-expressing PC12 cells.
The Journal of biological chemistry.
1993 Nov; 268(32):23891-7. doi:
10.1016/s0021-9258(20)80469-4. [PMID: 8226929] - J L Grem, N McAtee, S M Steinberg, J M Hamilton, R F Murphy, J Drake, T Chisena, F Balis, R Cysyk, S G Arbuck. A phase I study of continuous infusion 5-fluorouracil plus calcium leucovorin in combination with N-(phosphonacetyl)-L-aspartate in metastatic gastrointestinal adenocarcinoma.
Cancer research.
1993 Oct; 53(20):4828-36. doi:
NULL. [PMID: 8402669] - J Nelson, I A Qureshi, S Vasudevan, D S Sarma. The effects of various inhibitors on the regulation of orotic acid excretion in sparse-fur mutant mice (spf/Y) deficient in ornithine transcarbamylase.
Chemico-biological interactions.
1993 Oct; 89(1):35-47. doi:
10.1016/0009-2797(93)03195-z. [PMID: 8221965] - Y Chen, B Goz, L Kirkman. An analysis of vincristine-resistance in BHK cells pretreated with 1-beta-D-arabinofuranosylcytosine.
Anticancer research.
1993 Jan; 13(1):249-55. doi:
. [PMID: 8476220] - M E Perry, M Rolfe, P McIntyre, M Commane, G R Stark. Induction of gene amplification by 5-aza-2'-deoxycytidine.
Mutation research.
1992 May; 276(3):189-97. doi:
10.1016/0165-1110(92)90008-w. [PMID: 1374514] - J Nelson, I A Qureshi, S Vasudevan. [Mechanism of the effect of serine and threonine on ammoniagenesis and biosynthesis of orotate in the mouse].
Clinical and investigative medicine. Medecine clinique et experimentale.
1992 Apr; 15(2):113-21. doi:
NULL. [PMID: 1591893] - N Kemeny, K Seiter, D Martin, C Urmacher, D Niedzwiecki, R C Kurtz, P Costa, M Murray. A new syndrome: ascites, hyperbilirubinemia, and hypoalbuminemia after biochemical modulation of fluorouracil with N-phosphonacetyl-L-aspartate (PALA).
Annals of internal medicine.
1991 Dec; 115(12):946-51. doi:
10.7326/0003-4819-115-12-946. [PMID: 1824554] - A R Kinsella, M S Haran. Decreasing sensitivity to cytotoxic agents parallels increasing tumorigenicity in human fibroblasts.
Cancer research.
1991 Apr; 51(7):1855-9. doi:
NULL. [PMID: 2004369] - E S Casper, J Baselga, T B Smart, G B Magill, M Markman, A Ranhosky. A phase II trial of PALA + dipyridamole in patients with advanced soft-tissue sarcoma.
Cancer chemotherapy and pharmacology.
1991; 28(1):51-4. doi:
10.1007/bf00684956. [PMID: 2040033] - T J McMillan, T Kalebic, G R Stark, I R Hart. High frequency of double drug resistance in the B16 melanoma cell line.
European journal of cancer (Oxford, England : 1990).
1990; 26(5):565-7. doi:
10.1016/0277-5379(90)90077-7. [PMID: 2144741] - B Ardalan, G Singh, H Silberman. A randomized phase I and II study of short-term infusion of high-dose fluorouracil with or without N-(phosphonacetyl)-L-aspartic acid in patients with advanced pancreatic and colorectal cancers.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
1988 Jun; 6(6):1053-8. doi:
10.1200/jco.1988.6.6.1053. [PMID: 3373260] - L B Jacobsen, J E Putnam, D P Sawick, J M Cassady, D J Morré. Pyrimidine nucleosides enhance the efficacy of inhibitors of pyrimidine biosynthesis in cultured hepatocellular carcinoma cells.
Life sciences.
1988; 42(8):913-8. doi:
10.1016/0024-3205(88)90390-6. [PMID: 3343891] - E Giulotto, C Knights, G R Stark. Hamster cells with increased rates of DNA amplification, a new phenotype.
Cell.
1987 Mar; 48(5):837-45. doi:
10.1016/0092-8674(87)90080-8. [PMID: 3815526] - C Erichsen, P I Christensson, B Jakobsson, G Eriksson, T Yngner, P E Jönsson, U Stenram. Effect of N-phosphonacetyl-L-aspartate and D-glucosamine on the incorporation of 5-fluorouridine into normal tissues and an adenocarcinoma in the rat.
Anticancer research.
1987 Jan; 7(1):77-80. doi:
. [PMID: 3566186] - K Bhalla, S Grant. Effect of deoxycytidine on the in vitro response of human leukemia cells to inhibitors of de novo pyrimidine biosynthesis.
Cancer chemotherapy and pharmacology.
1987; 19(3):226-32. doi:
10.1007/bf00252977. [PMID: 3581416] - J M Karle, K H Cowan, C A Chisena, R L Cysyk. Uracil nucleotide synthesis in a human breast cancer cell line (MCF-7) and in two drug-resistant sublines that contain increased levels of enzymes of the de novo pyrimidine pathway.
Molecular pharmacology.
1986 Aug; 30(2):136-41. doi:
NULL. [PMID: 2874477] - T C Chan, M Markman, S Cleary, S B Howell. Plasma uridine changes in cancer patients treated with the combination of dipyridamole and N-phosphonacetyl-L-aspartate.
Cancer research.
1986 Jun; 46(6):3168-72. doi:
. [PMID: 3698032] - M J O'Connell, C G Moertel, J Rubin, R G Hahn, L K Kvols, A J Schutt. Clinical trial of sequential N-phosphonacetyl-L-aspartate, thymidine, and 5-fluorouracil in advanced colorectal carcinoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
1984 Oct; 2(10):1133-8. doi:
10.1200/jco.1984.2.10.1133. [PMID: 6491697] - F B Stehman, C E Ehrlich. Peritoneo-cystic shunt for malignant ascites.
Gynecologic oncology.
1984 Jul; 18(3):402-7. doi:
10.1016/0090-8258(84)90052-0. [PMID: 6204912] - A Holstege, D Manglitz, W Gerok. Depletion of blood plasma cytidine due to increased hepatocellular salvage in D-galactosamine-treated rats.
European journal of biochemistry.
1984 Jun; 141(2):339-44. doi:
10.1111/j.1432-1033.1984.tb08197.x. [PMID: 6734601] - B Ardalan, D Jamin, H N Jayaram, C A Presant. Phase I study of continuous-infusion PALA and 5-FU.
Cancer treatment reports.
1984 Mar; 68(3):531-4. doi:
NULL. [PMID: 6231102] - J C White, L H Hines. Role of endocytosis and lysosomal pH in uptake of N-(phosphonacetyl)-L-aspartate and its inhibition of pyrimidine synthesis.
Cancer research.
1984 Feb; 44(2):507-13. doi:
NULL. [PMID: 6692357] - J M Karle, L W Anderson, R L Cysyk. Effect of plasma concentrations of uridine on pyrimidine biosynthesis in cultured L1210 cells.
The Journal of biological chemistry.
1984 Jan; 259(1):67-72. doi:
10.1016/s0021-9258(17)43622-2. [PMID: 6323418] - R H Earhart, P J Elson, S N Rosenthal, R G Hahn, R E Slayton. Phase II study of PALA and AMSA in advanced renal cell carcinoma.
American journal of clinical oncology.
1983 Oct; 6(5):555-60. doi:
10.1097/00000421-198310000-00008. [PMID: 6688498] - A A Miller, E C Moore, R B Hurlbert, J A Benvenuto, T L Loo. Pharmacological and biochemical interactions of N-(phosphonacetyl)-L-aspartate and 5-fluorouracil in beagles.
Cancer research.
1983 Jun; 43(6):2565-70. doi:
. [PMID: 6189583] - E S Casper, K Vale, L J Williams, D S Martin, C W Young. Phase I and clinical pharmacological evaluation of biochemical modulation of 5-fluorouracil with N-(phosphonacetyl)-L-aspartic acid.
Cancer research.
1983 May; 43(5):2324-9. doi:
NULL. [PMID: 6831457] - R B Natale, A Yagoda, D P Kelsen, R J Gralla, R C Watson. Phase II trial of PALA in hypernephroma and urinary bladder cancer.
Cancer treatment reports.
1982 Dec; 66(12):2091-2. doi:
NULL. [PMID: 7139651] - E C Moore, J Friedman, M Valdivieso, W Plunkett, J R Marti, J Russ, T L Loo. Aspartate carbamoyltransferase activity, drug concentrations, and pyrimidine nucleotides in tissue from patients treated with N-(phosphonacetyl)-L-aspartate.
Biochemical pharmacology.
1982 Oct; 31(20):3317-21. doi:
10.1016/0006-2952(82)90567-6. [PMID: 7150358] - G Powis. Effect of human renal and hepatic disease on the pharmacokinetics of anticancer drugs.
Cancer treatment reviews.
1982 Jun; 9(2):85-124. doi:
10.1016/s0305-7372(82)80012-1. [PMID: 6181872] - G M Wahl, L Vitto, R A Padgett, G R Stark. Single-copy and amplified CAD genes in Syrian hamster chromosomes localized by a highly sensitive method for in situ hybridization.
Molecular and cellular biology.
1982 Mar; 2(3):308-19. doi:
10.1128/mcb.2.3.308-319.1982. [PMID: 6180304] - M Chadwick, D M Silveira, J A MacGregor, A R Branfman, R H Liss, D W Yesair. Comparative physiological disposition of N-(phosphonacetyl)-L-aspartate in several animal species after intravenous and oral administration.
Cancer research.
1982 Feb; 42(2):627-32. doi:
NULL. [PMID: 7055806] - C Erlichman, R C Donehower, J L Speyer, R Klecker, B A Chabner. Phase I-phase II trial of N-phosphonacetyl-L-aspartic acid given by intravenous infusion and 5-fluorouracil given by bolus injection.
Journal of the National Cancer Institute.
1982 Feb; 68(2):227-31. doi:
NULL. [PMID: 6950156] - G R Weiss, T J Ervin, M W Meshad, D Schade, A R Branfman, R J Bruni, M Chadwick, D W Kufe. A phase I trial of combination therapy with continuous-infusion PALA and continuous-infusion 5-FU.
Cancer chemotherapy and pharmacology.
1982; 8(3):301-4. doi:
10.1007/bf00254054. [PMID: 7127661] - J M Karle, L W Anderson, D D Dietrick, R L Cysyk. Effect of inhibitors of the de novo pyrimidine biosynthetic pathway on serum uridine levels in mice.
Cancer research.
1981 Dec; 41(12 Pt 1):4952-5. doi:
NULL. [PMID: 6171344] - J Lankelma, P G Penders, A Leyva, U R Kleeberg, J B Kenny, V Bramwell, J G McVie, H M Pinedo. Concentrations of N-(phosphonacetyl)-L-aspartate (PALA) in plasma and tears in man.
European journal of cancer & clinical oncology.
1981 Nov; 17(11):1199-204. doi:
NULL. [PMID: 7199467] - J D Moyer, J T Oliver, R E Handschumacher. Salvage of circulating pyrimidine nucleosides in the rat.
Cancer research.
1981 Aug; 41(8):3010-7. doi:
NULL. [PMID: 7248957] - B Ardalan, T W Kensler, H N Jayaram, W Morrison, D D Choie, M Chadwick, R Liss, D A Cooney. Long-term association of N-(phosphonacetyl)-L-aspartate with bone.
Cancer research.
1981 Jan; 41(1):150-6. doi:
NULL. [PMID: 7448755] - J Lankelma, P G Penders, A Leyva, H M Pinedo. Determination of N-(phosphonacetyl)-L-aspartic acid (PALA) in plasma and urine by high pressure liquid chromatography.
European journal of cancer.
1980 Nov; 16(11):1483-7. doi:
10.1016/0014-2964(80)90059-6. [PMID: 7227423] - D J Stewart, M Leavens, J Friedman, R S Benjamin, E C Moore, G P Bodey, M Valdivieso, M A Burgess, C Wiseman, T L Loo. Penetration of N-(phosphonacetyl)-L-aspartate into human central nervous system and intracerebral tumor.
Cancer research.
1980 Sep; 40(9):3163-6. doi:
NULL. [PMID: 7427934] - J M Karle, L W Anderson, C Erlichman, R L Cysyk. Serum uridine levels in patients receiving N-(phosphonacetyl)-L-aspartate.
Cancer research.
1980 Aug; 40(8 Pt 1):2938-40. doi:
NULL. [PMID: 7388844] - T W Kensler, C Erlichman, H N Jayaram, A K Tyagi, B Ardalan, D A Cooney. Peripheral leukocytes as indicators of the enzymatic effects of N-(phosphonacetyl)-L-aspartic acid (PALA) on human L-aspartate transcarbamoylase (ATCase) activity.
Cancer treatment reports.
1980 Aug; 64(8-9):967-73. doi:
NULL. [PMID: 7448831] - C Erlichman, J M Strong, B A Chabner. Application of a simple competitive protein-binding assay technique to the pharmacokinetics of N-(phosphonacetyl)-L-aspartate in humans.
Cancer research.
1980 Jun; 40(6):1902-6. doi:
NULL. [PMID: 7371023] - A R Branfman, R J Bruni, Y N Merrill, M Chadwick, J M Strong, T J Ervin. Quantitation of the antitumor agent N-(phosphonacetyl)-L-aspartic acid in human plasma and urine by gas chromatography-mass spectrometry-selected ion monitoring.
Journal of chromatography.
1980 May; 182(2):163-9. doi:
10.1016/s0378-4347(00)81620-5. [PMID: 7380909] - J Roboz, R Suzuki, E Rose. Mass spectrometric technique for the determination of N-phosphonoacetyl-L-aspartic acid in serum.
Journal of chromatography.
1980 Feb; 181(2):195-205. doi:
10.1016/s0378-4347(00)81605-9. [PMID: 7372753] - T W Kensler, H N Jayaram, D A Cooney. A facile enzymatic technique for the estimation of nanomolar concentrations of N-phosphonacetyl-L-aspartic acid in plasma.
Journal of biochemical and biophysical methods.
1980 Jan; 2(1):29-35. doi:
10.1016/0165-022x(80)90071-8. [PMID: 6999068] - C Erlichman. An overview of the clinical pharmacology of N-phosphonacetyl-L-aspartate (PALA), a new antimetabolite.
Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.
1980; 74(?):65-71. doi:
10.1007/978-3-642-81488-4_9. [PMID: 7444150] - T L Loo, J Friedman, E C Moore, M Valdivieso, J R Marti, D Stewart. Pharmacological disposition of N-(phosphonacetyl)-L-aspartate in humans.
Cancer research.
1980 Jan; 40(1):86-90. doi:
NULL. [PMID: 7349907] - J D Moyer, R E Handschumacher. Selective inhibition of pyrimidine synthesis and depletion of nucleotide pools by N-(phosphonacetyl)-L-aspartate.
Cancer research.
1979 Aug; 39(8):3089-94. doi:
NULL. [PMID: 455293] - J M Strong, Y E Kinney, A R Branfman, R L Cysyk. Determination of N-(Phosphonacetyl)-L-aspartic acid (PALA) in dog serum and urine by gas chromatography and selected lon monitoring.
Cancer treatment reports.
1979 May; 63(5):775-80. doi:
NULL. [PMID: 455314] - D A Cooney, M G Karlowicz, J Cubillan, M Roettger, H N Jayaram. An enzymatic technique for measuring N-phosphonacetyl-L-aspartic acid in tissues.
Cancer treatment reports.
1978 Oct; 62(10):1503-7. doi:
NULL. [PMID: 361225] - E A Swyryd, S S Seaver, G R Stark. N-(phosphonacetyl)-L-aspartate, a potent transition state analog inhibitor of aspartate transcarbamylase, blocks proliferation of mammalian cells in culture.
The Journal of biological chemistry.
1974 Nov; 249(21):6945-50. doi:
NULL. [PMID: 4371054]